{"id":156019,"date":"2021-10-05T18:18:57","date_gmt":"2021-10-05T22:18:57","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/terns-pharmaceuticals-to-present-at-h-c-wainwright-5th-annual-nash-investor-conference\/"},"modified":"2024-08-18T11:43:28","modified_gmt":"2024-08-18T15:43:28","slug":"terns-pharmaceuticals-to-present-at-h-c-wainwright-5th-annual-nash-investor-conference","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/terns-pharmaceuticals-to-present-at-h-c-wainwright-5th-annual-nash-investor-conference.php","title":{"rendered":"Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference"},"content":{"rendered":"<p><![CDATA[FOSTER CITY, Calif., Oct.  05, 2021  (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (\u201cTerns\u201d or the \u201cCompany\u201d) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that management will be presenting at the H.C. Wainwright 5th Annual NASH Investor Conference on Tuesday, October 12 at 2:30 p.m. ET.]]><\/p>\n<p>See the rest here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/www.globenewswire.com\/news-release\/2021\/10\/05\/2309131\/0\/en\/Terns-Pharmaceuticals-to-Present-at-H-C-Wainwright-5th-Annual-NASH-Investor-Conference.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference\">Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>See the rest here: Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/terns-pharmaceuticals-to-present-at-h-c-wainwright-5th-annual-nash-investor-conference.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-156019","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/156019"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=156019"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/156019\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=156019"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=156019"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=156019"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}